Khadija Iken is a seasoned Biotech consultant specializing in immunology and pharmacology, with over 15 years of extensive experience in chronic inflammation and immuno-oncology. Currently, she plays a pivotal role in guiding small biotech firms through the complexities of early clinical development, leveraging her deep...
Khadija Iken is a seasoned Biotech consultant specializing in immunology and pharmacology, with over 15 years of extensive experience in chronic inflammation and immuno-oncology. Currently, she plays a pivotal role in guiding small biotech firms through the complexities of early clinical development, leveraging her deep understanding of translational research and biomarker discovery. Khadija's expertise is not only reflected in her impressive portfolio of peer-reviewed publications but also in her ability to translate scientific knowledge into actionable strategies that drive innovation in drug development.
In her current position, Khadija provides strategic oversight and scientific expertise for various immunology and pharmacology programs, focusing on both in vitro and in vivo studies. Her proactive approach to staying abreast of the latest literature in chronic inflammation ensures that her contributions are grounded in the most current scientific advancements. She excels in developing and designing protocols and biomarker plans, which are critical for assay development and data analysis in pre-clinical studies. Her proficiency in techniques such as FACS, PCR, and mouse models enhances her ability to deliver robust data that informs clinical decision-making.
Khadija is not only a resourceful and analytical scientist but also a dedicated mentor who enjoys sharing her knowledge with junior scientists. Her commitment to fostering the next generation of researchers is evident in her active contributions to training programs and collaborative projects. By bridging the gap between scientific research and practical application, Khadija Iken continues to make significant strides in the biotech industry, particularly in advancing therapies for chronic inflammatory diseases and cancer.
